Abstract

Conduct an early Phase II study of Flunarizine (ADD 59076) that follows a final protocol jointly agreed upon by the NINCDS, Janssen Pharmaceutica, Inc., and the contractor. The study will obtain preliminary information regarding the tolerability and metabolism of Flunarizine in three groups of patients with partial seizures.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research and Development Contracts (N01)
Project #
N01NS012377-003004
Application #
3668915
Study Section
Project Start
1986-05-01
Project End
1987-12-31
Budget Start
1987-09-08
Budget End
1987-12-31
Support Year
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095